Marginal Zone Lymphoma (MZL)
Marginal zone lymphoma (MZL), also known as marginal zone B-cell lymphoma, is a rare subtype of lymphoid malignancy that arises from the marginal zone B cells. We are very proud of our specialized technology platform and experts, specializing in providing marginal zone lymphoma (MZL) therapy and developing animal models to meet the needs of biological experts and researchers. With our extensive knowledge and unwavering dedication to customization, we offer bespoke solutions that precisely align with your distinctive research requirements.
Introduction to Marginal Zone Lymphoma (MZL)
Marginal zone lymphoma (MZL) is a type of non-Hodgkin lymphoma that primarily affects the marginal zone B cells in the lymphoid tissue. The age-standardized incidence of MZL was 19.6/1 million person-years. It is characterized by the infiltration of malignant B cells in the marginal zone, which is the area surrounding the germinal centers. MZL accounts for approximately 12% of all non-Hodgkin lymphomas and can occur in various organs, including the spleen, lymph nodes, and mucosal tissues.
Pathogenesis of Marginal Zone Lymphoma (MZL)
Mutations in genes related to the NF-κB signaling pathway, such as CARD11 and TNFAIP3, have been observed in a subset of MZL cases. These mutations contribute to the dysregulation of immune response and cell survival signals, promoting the development and progression of MZL. Additionally, chronic antigenic stimulation, particularly in the context of autoimmune diseases or chronic infections, has been implicated in the pathogenesis of MZL. Stimulating B cells by antigens leads to the activation and expansion of marginal zone B cells, which can undergo malignant transformation.
Fig.1 Mechanism of drug action of MZL. (Cheah, Chan Y., et al., 2022)Subtypes of Marginal Zone Lymphoma (MZL)
MZL can be further classified into three main subtypes based on the site of involvement: mucosa-associated lymphoid tissue (MALT lymphoma), splenic MZL, and nodal MZL.
MALT lymphoma
MALT lymphoma primarily affects extranodal sites, such as the stomach, lung, salivary glands, and ocular adnexa. It is commonly associated with chronic inflammation, autoimmune diseases, or infections.
Splenic MZL
Splenic MZL primarily involves the spleen and often presents with splenomegaly. It is associated with specific genetic alterations, including mutations in NOTCH pathway genes and KLF2 transcription factor mutation.
Nodal MZL
Nodal MZL primarily affects the lymph nodes and can be associated with autoimmune diseases. It is characterized by the involvement of multiple lymph nodes, often in an indolent fashion.
Targeted Development of Marginal Zone Lymphoma (MZL)
- The dysregulated NF-κB signaling pathway, resulting from genetic alterations, has emerged as a potential target for therapy. Various agents, including proteasome inhibitors and BTK inhibitors, have shown promising results in targeting NF-κB signaling in MZL.
- The B-cell receptor (BCR) signaling pathway plays a crucial role in the survival and proliferation of malignant B cells in MZL. Inhibitors targeting key components of the BCR pathway, such as BTK inhibitors and PI3K inhibitors, have demonstrated efficacy in MZL.
Our Services
Our company is delighted to extend our comprehensive range of services encompassing the intricate realm of MZL diagnostics and therapy development. From the pivotal stages of target identification and validation to the rigorous preclinical trials, our company ensures an all-encompassing approach to empower breakthrough innovations in MZL therapies. We grasp the profound intricacies of this multifaceted condition and collaborate closely with esteemed professionals like yourself to forge a path toward pioneering, efficacious therapeutics.
MZL Therapy Development Platforms
Leveraging the prowess of our cutting-edge animal model development platform, we have proudly curated an exquisite repertoire of specialized animal models tailored specifically for MZL. These meticulously crafted models epitomize utmost fidelity in mirroring the intricate nuances of the disease's characteristics, thereby bestowing upon researchers and drug developers invaluable platforms for meticulous drug safety assessments and intricate pharmacokinetic analyses.
Animal Models of MZL
- Splenic MZL (SMZL) models
- Nodal MZL (NMZL) models
- Extranodal MZL (EMZL) models
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Cheah, Chan Y., et al. "Marginal zone lymphoma: present status and future perspectives." Haematologica 107.1 (2022): 35.
- Sindel, Ariel, Taha Al-Juhaishi, and Victor Yazbeck. "Marginal zone lymphoma: state-of-the-art treatment." Current Treatment Options in Oncology 20 (2019): 1-15.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.